Docebo Announces Pricing of Upsized Initial Public Offering in the United States and Public Offering in Canada
Summary
The common shares of Docebo are expected to begin trading on The Nasdaq Global Select Market (the “Nasdaq”) under the symbol "DCBO" on December 3, 2020, and will continue to trade on the Toronto Stock Exchange (the “TSX”) under the symbol "DCBO". Docebo expects that the net proceeds of the offering will be used primarily to strengthen the Companys financial position and allow it to pursue its growth strategies, which include: expanding its customer base; supporting the growth of existing customers; expanding its solutions; and other general corporate purposes. Copies of the final prospectus supplement will be filed on SEDAR, and on EDGAR as part of an amended registration statement on Form F-10/A. Copies of such documents may also be obtained from any of the following sources: Morgan Stanley & Co. LLC, Attn: Prospectus Department - 180 Varick Street, 2nd Floor - New York, NY 10014; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 1-866-471-2526 or by e-mail at prospectus-ny@ny.email.gs.com; and Canaccord Genuity LLC, Attention: Syndicate Department, 99 High Street, 12th Floor, Boston MA 021990, by email at prospectus@cgf.com. This forward-looking information is based on our opinions, estimates and assumptions that, while considered by the Company to be appropriate and reasonable as of the date of this press release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including, without limitation: risks related to the COVID-19 pandemic and its impact on Docebo, economic conditions, and global markets; the failure of Docebo and/or the underwriters to satisfy closing conditions to the offering; the failure of Docebo to satisfy certain Nasdaq and/or TSX listing requirements; the failure of Docebo to use any of the proceeds received from the offering in a manner consistent with current expectations; and other unforeseen events, developments, or factors causing any of the aforesaid expectations, assumptions, and other factors ultimately being inaccurate or irrelevant and those factors discussed in greater detail under the “Risk Factors” section of the prospectus supplement dated December 1, 2020 and our Annual Information Form for the year ended December 31, 2019, each available under our profile on SEDAR at www.sedar.com, and should be considered carefully by prospective investors.
Classifications
AskAI Classifications
LabelsLinked Companies
